Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

The journey to triple protection in type 2 diabetes starts at the kidneys

Invokana offers triple protection in T2DM against renal events, CV events and elevated HbA1c1

Invokana is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus as an
adjunct to diet and exercise:

  • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • in addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies,
effects on glycaemic control, cardiovascular and renal
events, and the populations studied, see sections 4.4, 4.5 and 5.1 of the SmPC.1



Prescribing information can be accessed by clicking the PI links at the bottom of this webpage.

Kidney Heart and Blood Drop

About Invokana

Mode of Action Icon

Mode of Action

Know More
Indication & dosing icon

Indication & Dosing

Know More
Indication & dosing icon

Safety & tolerability

Know More

A Journey to Triple Protection with Invokana

Why Choose Invokana


Invokana was the first SGLT2 inhibitor licensed to treat DKD in Type 2 Diabetes patients following publication of the CREDENCE trial

Know More

Invokana eliminates more blood glucose every day than any other SGLT2i1-5

Know More

Invokana gets more patients to HbA1c target than any other SGLT2i as add-on to metformin1-4

Know More

Reduces the risk of major CV events over the long term (up to 6.5 years)6

Know More

HCP Resources

This section provides useful resources to help you provide optimal care.

Doctor and Patient

Patient Information

For your patients who have been prescribed Invokana for the treatment of insufficiently controlled type 2 diabetes.



In this section you will discover a selection of articles that you will find useful in helping you to optimise the care of your patients.


CV: Cardiovascular; DKD: Diabetic Kidney Disease; HbA1c: Haemoglobin A1c; SGLT2i: Sodium-Glucose Co-Transporter 2 inhibitor; SmPC: Summary of Product Characteristics; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/Creatinine Ratio.


Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or